Avacta Group, the developer of Affimer biotherapeutics and research reagents, has appointed Professor Gerard Evan, FRS, to its therapeutics scientific advisory board.

Avacta says Evan brings world-leading expertise in immuno-oncology and cancer stem cell research to support the froup's development of oncology biotherapeutics based on its proprietary Affimer technology.

Evan's research focuses on the molecular basis of cancer. He was formerly Gerson and Barbara Bass Baker Distinguished Professor of Cancer Biology at the University of California San Francisco and Co-leader of the Cell Cycling and Signaling Program at the UCSF Comprehensive Cancer Center. In 2009 he was elected to the Sir William Dunn Chair of Biochemistry and Head of Biochemistry in the University of Cambridge.

Evan has a BA in Biochemistry from the University of Oxford and a PhD in Molecular Immunology from the University of Cambridge. He was awarded the Pfizer prize in Biology in 1995, and in 1996 was elected as the Royal Society's Napier Professor of Cancer Research.

He is a Fellow of the Royal Society, the UK Academy of Medical Sciences and the European Molecular Biology Organization. Professor Evan has also held the Neal Levitan Research Chair of the Brain Tumor Society and a Senior Scholarship from the Ellison Medical Research Foundation for Ageing.


At 9:02am: (LON:AVCT) Avacta Group PLC share price was 0p at 94p